Literature DB >> 31707337

Magnoflorine improves sensitivity to doxorubicin (DOX) of breast cancer cells via inducing apoptosis and autophagy through AKT/mTOR and p38 signaling pathways.

Tian Wei1, Xie Xiaojun2, Cao Peilong3.   

Abstract

Breast cancer is a leading cause of cancer death among women worldwide. Doxorubicin (DOX) is a broad-spectrum anti-breast cancer agent, but its clinical use is restricted due to irreversible tissue toxicity. Thereby, new therapeutic approaches are urgently required to promote the sensitivity of breast cancer cells to DOX. Magnoflorine (Mag), a quaternary alkaloid isolated from Chinese herb Magnolia or Aristolochia, has various biological activities, such as anti-inflammation, anti-cancer, and anti-anxiety. In the study, we explored the effects Mag on the sensitivity of breast cancer cells to DOX. We demonstrated that Mag strongly promoted DOX-induced anti-proliferative effects in breast cancer cells while not in normal cells. Mag addition markedly promoted the effects of DOX on the inhibition of migration and invasion in breast cancer cells. DOX-triggered DNA damage in breast cancer cells was further accelerated by combination with Mag. DOX-induced cell distribution in G2/M phase was markedly elevated when co-treated with Mag. Additionally, DOX/Mag combinational treatment significantly induced apoptosis in breast cancer cells when compared to DOX alone group through inducing Caspase-3 cleavage. Moreover, Mag markedly promoted the role of DOX in autophagy induction by elevating light chain 3 (LC3)-II expression. Combination treatment with DOX and Mag significantly inhibited the activation of phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling, and promoted p38 mitogen-activated protein kinase (MAPK) pathway. In addition, treatment with wortmannin (Wor, a blocker of autophagosome formation) markedly reduced DOX/Mag-induced p38 MAPK activation and LC3 conversion in breast cancer cells. Further, in MCF-7 xenograft model, DOX combined with Mag displayed a significant anti-tumor effect with little toxicity to organs such as liver, heart, kidney and spleen. These findings suggested that Mag promoted the anti-cancer effects of DOX to induce cellular apoptosis and autophagy in breast cancer cells.
Copyright © 2019. Published by Elsevier Masson SAS.

Entities:  

Keywords:  AKT/mTOR and p38; Apoptosis and autophagy; Breast cancer; Doxorubicin; Magnoflorine

Mesh:

Substances:

Year:  2019        PMID: 31707337     DOI: 10.1016/j.biopha.2019.109139

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  22 in total

1.  Lysophosphatidic acid protects cervical cancer HeLa cells from apoptosis induced by doxorubicin hydrochloride.

Authors:  Xibo Wang; Haihua Wang; Xiaoxiao Mou; Yilin Xu; Wenbo Han; Aimin Huang; Yanwei Li; Hui Jiang; Xiaoyun Yang; Zhenbo Hu
Journal:  Oncol Lett       Date:  2022-06-17       Impact factor: 3.111

2.  Downregulation of miR-7-5p Inhibits the Tumorigenesis of Esophagus Cancer via Targeting KLF4.

Authors:  Woda Shi; Jianxiang Song; Zhengya Gao; Xingchen Liu; Wencai Wang
Journal:  Onco Targets Ther       Date:  2020-09-24       Impact factor: 4.147

3.  Synergistic or Additive Pharmacological Interactions between Magnoflorine and Cisplatin in Human Cancer Cells of Different Histological Origin.

Authors:  Estera Okon; Jarogniew J Luszczki; Wirginia Kukula-Koch; Marta Halasa; Agata Jarzab; Daariimaa Khurelbat; Andrzej Stepulak; Anna Wawruszak
Journal:  Int J Mol Sci       Date:  2020-04-19       Impact factor: 5.923

4.  Magnoflorine-Isolation and the Anticancer Potential against NCI-H1299 Lung, MDA-MB-468 Breast, T98G Glioma, and TE671 Rhabdomyosarcoma Cancer Cells.

Authors:  Estera Okon; Wirginia Kukula-Koch; Marta Halasa; Agata Jarzab; Marzena Baran; Magdalena Dmoszynska-Graniczka; Apostolis Angelis; Eleftherios Kalpoutzakis; Malgorzata Guz; Andrzej Stepulak; Anna Wawruszak
Journal:  Biomolecules       Date:  2020-11-10

Review 5.  Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery.

Authors:  Sepideh Mirzaei; Ali Zarrabi; Farid Hashemi; Amirhossein Zabolian; Hossein Saleki; Negar Azami; Soodeh Hamzehlou; Mahdi Vasheghani Farahani; Kiavash Hushmandi; Milad Ashrafizadeh; Haroon Khan; Alan Prem Kumar
Journal:  Antioxidants (Basel)       Date:  2021-02-26

6.  Blockage of AMPK-ULK1 pathway mediated autophagy promotes cell apoptosis to increase doxorubicin sensitivity in breast cancer (BC) cells: an in vitro study.

Authors:  Libo Yu; Qingtao Shi; Yan Jin; Zhixin Liu; Jiaxin Li; Wenzhou Sun
Journal:  BMC Cancer       Date:  2021-02-25       Impact factor: 4.430

7.  Magnoflorine Ameliorates Inflammation and Fibrosis in Rats With Diabetic Nephropathy by Mediating the Stability of Lysine-Specific Demethylase 3A.

Authors:  Liang Chang; Qi Wang; Jiannan Ju; Yue Li; Qiao Cai; Lirong Hao; Yang Zhou
Journal:  Front Physiol       Date:  2020-12-22       Impact factor: 4.566

8.  The Oxygen-Generating Calcium Peroxide-Modified Magnetic Nanoparticles Attenuate Hypoxia-Induced Chemoresistance in Triple-Negative Breast Cancer.

Authors:  Fong-Yu Cheng; Chia-Hsin Chan; Bour-Jr Wang; Ya-Ling Yeh; Ying-Jan Wang; Hui-Wen Chiu
Journal:  Cancers (Basel)       Date:  2021-02-03       Impact factor: 6.639

9.  Identification of drug targets and potential molecular mechanisms for Wantong Jingu Tablet extract in treatment of rheumatoid arthritis: bioinformatics analysis of fibroblast-like synoviocytes.

Authors:  Zhaodong Li; Fangyuan Qi; Fan Li
Journal:  Chin Med       Date:  2020-06-05       Impact factor: 5.455

10.  New Cytotoxic Cerebrosides from the Red Sea Cucumber Holothuria spinifera Supported by In-Silico Studies.

Authors:  Reda F A Abdelhameed; Enas E Eltamany; Dina M Hal; Amany K Ibrahim; Asmaa M AboulMagd; Tarfah Al-Warhi; Khayrya A Youssif; Adel M Abd El-Kader; Hashim A Hassanean; Shaimaa Fayez; Gerhard Bringmann; Safwat A Ahmed; Usama Ramadan Abdelmohsen
Journal:  Mar Drugs       Date:  2020-08-01       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.